Samalizumab produced dose-dependent decreases in CD200 expression on CLL cells and decreased frequencies of circulating CD200 + CD4+ T cells that were sustained at higher doses. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.